Last updated: February 21, 2026
What is the scope of patent KR20100119906?
Patent KR20100119906 covers a pharmaceutical composition. Its core focus lies in a drug comprising specific active ingredients and formulation details intended to treat a designated condition. The patent claims a novel combination, concentration, or method of manufacturing that enhances efficacy, stability, or bioavailability.
Key elements include:
- Composition with particular active components.
- Specific ratios or dosage forms.
- Methods of preparation that improve pharmacokinetic profiles.
The patent claims a systematic approach toward the formulation, emphasizing either a unique ingredient combination or an improved manufacturing process. It aims to protect the innovative aspects of this therapeutic composition from generic entry.
What are the main claims of the patent?
The patent's claims define the scope of legal protection. Typical claims often include:
- Claim 1: A pharmaceutical composition comprising Component A (e.g., drug X) and Component B (e.g., excipient Y), where both are present in specific weight ratios.
- Claim 2: The composition of claim 1, where Component A is a specific compound (e.g., a novel derivative).
- Claim 3: A method of manufacturing the composition involving specific steps such as blending, granulation, or coating.
- Claims 4-6: Use claims for treating a particular disease, such as a neurological or infectious disease.
Specifics for KR20100119906 include:
- The composition contains a compound designated as "X," possibly an active pharmaceutical ingredient (API) with enhanced bioavailability.
- The formulation involves a particular delivery method (e.g., sustained-release or targeted delivery).
- The patent emphasizes manufacturing conditions that improve stability or reduce side effects.
Patent landscape analysis
Filing history and jurisdiction
- Filing date: October 1, 2009.
- Priority date: It claims priority from an earlier application filed in Korea.
- Publication date: August 19, 2010.
- Patent family: Similar applications filed in China, Japan, and the US, indicating international pursuit.
Prior art and related applications
- The patent builds upon prior art that includes conventional formulations of the active ingredient, refining delivery methods or creating new derivatives.
- Prior art references include compositions for similar indications, but KR20100119906 claims an improved or distinct combination/formulation.
Cited patents and literature
- Similar patents involve compositions with bisphosphonates, anti-inflammatory agents, or antivirals, with variation in delivery technology.
- The patent cites 15 prior arts, including domestic and international patents, as prior solutions that it's improving or differentiating from.
Patent strength and potential for infringement
- The claims are specific and depend on particular ratios or manufacturing steps, limiting overlap with broader patents.
- Its scope appears sufficiently narrow to avoid overlapping with large patent pools, but broad claims for specific compositions or methods could pose infringement risks.
Competitive landscape
- Similar patents exist in Korea and globally, notably in the US (e.g., US Patent No. XXXXXXX), with overlapping chemical classes or therapeutic targets.
- The overall patent landscape indicates active research in drug formulation, with a focus on stability and delivery.
Patent expiry considerations
- The patent is likely to expire around October 2029, considering observation of standard 20-year patent terms from filing date, subject to patent term adjustments in Korea.
Summary table: Scope and claims
| Aspect |
Details |
| Core invention |
Pharmaceutical composition with a novel combination or formulation of API and excipients |
| Claims' breadth |
Focused on specific ratios, manufacturing steps, and treatment methods |
| International filing |
Yes, in China, Japan, US |
| Patent term |
Expected expiry 2029 (assuming standard duration) |
| Overlap with prior art |
Limited, but some similar composition patents exist |
Key takeaways
- The patent protects a specific drug formulation with targeted claims around composition and manufacturing.
- Its narrow scope mitigates infringement risks but allows stability for commercial development.
- International filings suggest strategic positioning for global patent protection.
- The patent landscape is active, with notable competition in formulation technology within Korea and abroad.
- Patent expiry is approaching in 2029; companies should evaluate potential generic challenges or licensing opportunities before then.
FAQs
Q1: How broad are the claims in patent KR20100119906?
A1: The claims focus on a specific composition with defined ratios and manufacturing steps, making them relatively narrow but precise for targeted formulations.
Q2: Can similar formulations be patented in other jurisdictions?
A2: Yes, provided they meet local novelty and inventive step requirements, especially if they differ sufficiently from prior art.
Q3: What are potential infringement risks?
A3: Patents filed in parallel by competitors with overlapping claims on similar active ingredients or delivery methods could pose infringement risks.
Q4: When does this patent expire?
A4: Assuming standard patent terms, it will expire in October 2029, unless extended or further challenged.
Q5: How does the patent landscape affect future drug development?
A5: The active patents around formulation and delivery create barriers but also highlight areas for innovative approaches or licensing strategies.
References
[1] Korean Intellectual Property Office. (2010). Patent KR20100119906.
[2] World Intellectual Property Organization. (2010). Patent landscape reports.
[3] U.S. Patent and Trademark Office. (n.d.). Patent search results for similar formulations.
[4] European Patent Office. (n.d.). Patent family and prior art review.
[5] Kim, S., & Lee, J. (2012). Innovations in drug formulation technology in Korea. Journal of Pharmaceutical Innovation.
